Excellere Portfolio Company, Biocare Medical, Appoints Nicolas Barthelemy as Executive Chairman

October 14, 2019 Off By BusinessWire

PACHECO, Calif.–(BUSINESS WIRE)–Biocare Medical (“Biocare”), a leading developer of world-class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, announced today the appointment of Nicolas Barthelemy as Executive Chairman. Mr. Barthelemy brings over 25 years of executive leadership experience in the life sciences and diagnostic tools industry. He most recently served as CEO & President of Biotheranostics, a molecular diagnostics company. Additionally, Mr. Barthelemy held multiple executive leadership positions at Life Technologies, a leading developer of Life Science solutions, including roles as Chief Commercial Officer and President of the Cell Systems Division. Prior to leading commercial operations for Life Technologies, Mr. Barthelemy served in senior leadership roles at Biogen and Merck.

As Executive Chairman, Mr. Barthelemy will provide Biocare with strategic leadership as it continues to execute its vision as the preeminent provider of IHC reagents and instrumentation focused on clinical diagnostics and research in the oncology and immunotherapy sectors. “Nicolas has been a key member of Biocare’s board since joining the team in April 2018, and we are excited about the impact he will have in his expanded role with the organization,” said Ryan Glaws, Partner at Excellere Partners. “His extensive industry experience within the life science tools space and proven track record of driving growth across multiple organizations make him an ideal leader to support Biocare during this period of rapid expansion.”

“Biocare has reached an exciting inflection point in the company’s history, driven by its commitment to providing the highest quality IHC reagents and associated instrumentation solutions for the clinical diagnostic, research and pharma markets. I look forward to supporting the management team in executing on our mission to drive positive outcomes for the patients and families that have seen their lives forever altered by a cancer diagnosis,” said Mr. Barthelemy.